Lisa L.Furby

Associate

Chicago + 1.312.269.1525

Throughout her career, Lisa Furby has developed the skills needed to quickly master sophisticated technology and complex legal issues in the intellectual property field. Lisa can distill even the most technical issue into clear, concise, and easily understandable information for audiences with all levels of technical experience. She uses this skill to transform technically complicated facts and arguments into engaging stories for briefs, trial presentations, and oral arguments. But even as Lisa creates these compelling narratives, she keeps her focus on the big picture and the long-term strategy: developing a compelling record for the judge or jury on which to base their decision, and which preserves issues and postures the case for appeal.

One subject area in which Lisa has developed niche experience is §112 of the Patent Act. She has developed a reputation as a go-to lawyer for high-stakes matters involving issues related to the sufficiency of a patent's disclosure. Whether she is working on matters on which she is a regular team member, or as an internal advisor in the Firm, Lisa is in high demand for her insight on written description and enablement issues.

Lisa is also actively engaged in developing the next generation and especially in mentoring and supporting women who practice IP law. Lisa serves on the associates committee of Jones Day's "Women in IP" speaker series. She has also planned and participated in additional programs focused on mentoring junior associates, and particularly women, interested in IP litigation.

Experience

  • Merck resolves trade secret dispute involving vaccineJones Day represented Merck Sharp & Dohme Corp. as plaintiff in a trade secret lawsuit filed in the Eastern District of Pennsylvania against Pfizer Inc. and a former Merck employee.
  • Merck unit resolves DJ action involving pneumococcal vaccine patentsJones Day represented Merck Sharp & Dohme Corp. in an action in Delaware district court against Pfizer (through its subsidiaries including Wyeth, LLC) involving several patents on Wyeth’s vaccine technology.
  • Ricoh USA defends infringement claims involving 19 patents relating to office printer technologyJones Day is defending Ricoh USA, Inc. in a series of patent infringement cases involving office and production printer technology.
  • Allergan defends JUVEDERM® patents against nine IPR petitions filed by ProlleniumJones Day is representing Allergan, Inc. before the U.S. Patent Trial and Appeal Board ("PTAB") on nine IPR petitions filed by Prollenium challenging multiple patents covering certain of Allergan's JUVEDERM® products, hyaluronic acid-based dermal fillers that include the anesthetic lidocaine.
  • Idenix wins $2.54 billion jury verdict in Gilead patent dispute involving hepatitis C drugsAfter a nine day trial and less than two hours of jury deliberation, Jones Day, on behalf of Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co.), won the largest patent infringement verdict in U.S. history to date, involving a multi-billion dollar patent dispute with Gilead Sciences Inc. over sofosbuvir, the active ingredient in Gilead’s hepatitis C drugs Sovaldi® and Harvoni®.
  • AbbVie successfully defends HUMIRA® formulation patent against four IPR petitions filed by CoherusJones Day is serving as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®.
  • Mando resolves multipatent infringement suit filed by Robert Bosch GmbHJones Day represented Mando Corporation and Mando America (collectively "Mando") in the defense of a multipatent infringement suit filed by Robert Bosch GmbH in September 2016 relating to antilock braking systems.
  • BioMarin resolves patent infringement claims against Par Pharmaceutical related to Kuvan®Jones Day client BioMarin Pharmaceutical, Inc. successfully resolved a patent infringement action against Par Pharmaceutical, Inc. relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU).
  • BioMarin asserts patent infringement claims against Dr. Reddy's Laboratories related to Kuvan®Jones Day represented BioMarin Pharmaceutical, Inc. in a patent infringement action against Dr. Reddy's Laboratories relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic versions of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU).